Start-Up Quarterly Statistics, Q3 2010
This article was originally published in Start Up
Executive Summary
Biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million in Q3 2010, a 29% jump from the previous quarter and a 50% increase from Q3 2009. A total of eight start-up acquisitions closed in Q3, quite a jump from the first two quarters of 2010. The third quarter saw 14 biopharma alliances covering a wide range of therapeutic categories, the most popular indication being cancer.
You may also be interested in...
Pharma: Serious About Change?
Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.
The How And When Of Applying Sequencing To Clinical Diagnostics
Gene sequencing instrument providers are currently at the center of a range of corporate activities: acquisition, partnering, financing. As technology innovation continues, costs decrease, and the pace and scope of clinical genomic studies picks up, the notion of sequencing as the foundation for a clinical diagnostics platform is gaining more support. Delivering value to diagnostics customers ultimately may demand that instrument providers move downstream, involving themselves in data analysis and workflow and even test development, to prime the clinical market.
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
With funds and firms closing, a new reality awaits those who survive until the next economic upswing. Some of the elements are already in place, such as VCs' willingness to take capped returns and exits via risk-sharing contingency-based acquisitions. The emphasis on capital efficiency may change the types of companies VCs can afford to back, and corporate funds are now a vital part of biotech venture, especially in the early stages.